EGFR inhibition and more: a new generation growing up

Deborah Enting, James Spicer*

*Corresponding author for this work

Research output: Contribution to journalEditorialpeer-review

2 Citations (Scopus)

Abstract

The discovery of activating epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) has led to a shift in treatment paradigm for some patients with advanced disease. Mutations in exons 18-21 in the tyrosine kinase domain are associated with improved clinical outcomes following treatment with tyrosine kinase inhibitors (TKIs). The first-generation EGFR TKIs erlotinib and gefitinib are most effective in the presence of EGFR mutations (1).
Original languageEnglish
Pages (from-to)553-555
Number of pages3
JournalJournal of Thoracic Disease
Volume4
Issue number6
DOIs
Publication statusPublished - Dec 2012

Keywords

  • CELL LUNG-CANCER
  • TYROSINE KINASE INHIBITORS
  • GEFITINIB
  • MUTATIONS
  • ERLOTINIB
  • RESISTANCE
  • MODELS
  • GENE

Fingerprint

Dive into the research topics of 'EGFR inhibition and more: a new generation growing up'. Together they form a unique fingerprint.

Cite this